KEY TAKEAWAYS A Phase 3 trial found AstraZeneca's experimental lung cancer drug datopotamab deruxtecan did not significantly ...

AstraZeneca’s Phase 3 study in bladder cancer, showed that giving Imfinzi — before and after surgery — cut the risk of death.

The share price of AstraZeneca took a big hit on Tuesday after investors reacted to disappointing news from the company's ...

Shares of AstraZeneca PLC ($GB:AZN) fell by over 3% as of writing after the pharma company released an unsatisfactory outcome ...

AstraZeneca's Dato-DXd faces challenges in overall survival data but holds potential for approval with promising PFS benefits ...

AstraZeneca Plc (NASDAQ:AZN) shared detailed results from the TROPION-Lung01 Phase 3 of datopotamab deruxtecan (Dato-DXd) ...

London-listed AstraZeneca shares fell more than 5% on Tuesday after results from the company's lung cancer trials showed that ...

Paid and presented by AstraZeneca. When Cleusa was diagnosed with advanced lung cancer, she needed support attending her appointments in the city. Find out how a respiratory programme is helping to ...

A phase 3 trial of Daiichi Sankyo and Merck & Co.’s HER3-directed antibody-drug conjugate (ADC) has hit its primary endpoint, ...

LONDON, Sept 9 (Reuters) - Detailed results from one of AstraZeneca's (AZN.L), opens new tab key lung cancer trials released on Monday showed that its experimental precision drug did not ...

AstraZeneca’s Imfinzi recently became the first PD-1/L1 inhibitor to deliver a patient survival win in muscle-invasive ...

Shares in AstraZeneca dropped nearly 5 per cent on Tuesday after its failure to hit a target in trials for a next-generation ...